CT120

CT120 is an investigational autologous dual-target chimeric antigen receptor (CAR)-T cell therapy developed by IASO Biotherapeutics. It is engineered to target both CD19 and CD22 antigens on B cells using two fully human single-chain variable fragments (scFv) in its extracellular domain. This dual targeting aims to reduce the risk of antigen escape and tumor relapse that can occur with mono-specific CAR-T therapies by ensuring that tumor cells expressing either or both antigens are targeted for destruction. The intracellular signaling domains include 4-1BB and CD3ζ, which are designed to improve CAR-T cell viability and persistence while reducing neurotoxicity compared to other costimulatory signals like CD28. Upon binding to its targets, CT120 mediates tumor cell lysis through granzyme and perforin release and promotes further proliferation of CAR-T cells via cytokine secretion. It is being developed primarily for relapsed/refractory B-cell malignancies such as B-cell non-Hodgkin lymphoma (B-NHL) and B-cell acute lymphoblastic leukemia (B-ALL), with ongoing clinical trials in China at phase 1/2 stages[1][2][3][4][5][6][7].

Other names

fully human anti-CD19/CD22 dual target chimeric antigen receptor autologous T cell injectionfully human anti-CD19 x anti-CD22 dual targeted CAR-T cell productfully human, bivalent loop bi-CAR-T targeting both CD19 and CD22CD19/CD22 dual-targeted CAR T cellsdual-specific CAR T-cell therapy targets CD19 and CD22bispecific CAR T cells simultaneously recognizing CD19- and CD22-expressing targetstandem CD19/CD22 CAR-T cellsbi-specific CAR-T cell therapy targeting CD19 and CD22